Shared on01 Aug 25Fair value Increased 18%
Driven by a substantial increase in net profit margin and a marked reduction in the forward P/E multiple, Galderma Group’s fair value estimate has notably risen to CHF134.24. What's in the News Raised 2025 net sales growth guidance to 12-14% at constant currency, citing strong performance in Injectable Aesthetics and launch of Nemluvio in Therapeutic Dermatology; expects Neuromodulators segment to grow in low ‘teens’ percent for the year.